Abstract：Objective: To explore the effects of moxifloxacin in the treatment of chronic obstructive pulmonary disease (COPD) patients with respiratory failure on lung function, oxygen metabolism, serum C-reactive protein (CRP), creatine kinase (CK), lactate dehydrogenase (LDH), and neutrophils (NBC) level. Methods: 62 COPD patients with respiratory failure admitted between March 2018 and March 2020 were selected as the research objects, and were simply randomly divided into observation group and control group, with 31 cases in each group, using a random number table. Patients in the two groups received conventional treatment. Patients in the control group were treated with aerosol inhalation of salbutamol sulfate, and patients in the observation group were treated with aerosol inhalation of moxifloxacin. The differences in lung function, oxygen metabolism indexes, serum CRP, CK, LDH, and NBC levels before and after treatment were compared between the two groups of patients and the clinical efficacy. Results: Before treatment, there was no significant difference in the levels of FVC, FEV1, FEV1/FVC, CaO2, VO2 Max, ERO2, serum CRP, CK, LDH, and NBC between the two groups of patients (P>0.05); The levels of FVC, FEV1, FEV1/FVC, and CaO2 were higher than before treatment, and the increase in the observation group was greater, while the VO2 Max, ERO2, serum CRP, CK, LDH, and NBC levels of the two groups of patients were lower than before treatment. The degree of reduction in the observation group was greater, and the difference was statistically significant (P<0.05). The difference in efficacy between the two groups of patients was statistically significant (P<0.05). The total effective rate of clinical efficacy in the observation group was 96.77%, which was significantly higher than that of the control group (80.65%). The difference was statistically significant (P<0.05) . Conclusion: Moxifloxacin has a significant effect in the treatment of COPD patients complicated with respiratory failure, which can effectively improve patients' lung function, oxygen metabolism, and improve patients' serum CRP, CK, LDH, and NBC levels. It is worthy of clinical promotion.
马菲菲, 史亮. 莫西沙星治疗COPD合并呼衰对患者肺功能氧代谢及血清CRP CK LDH NBC水平的影响[J]. 河北医学, 2021, 27(6): 896-900.
MA Feifei, SHI Liang. Moxifloxacin on Lung Function Oxygen Metabolism and Serum CRP CK LDH NBC Levels of COPD Patients with Respiratory Failure. HeBei Med, 2021, 27(6): 896-900.
2021, Vol. 27 
冀公网安备13080202000677号